COMP <GO>
AMRX vs AXSM // EV/EBITDA & P/E VALUATION
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Axsome Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AMRX 6
— AXSM 5
■ METRIC PARITY
LAST: $20.44 (-4.97%) • MKT CAP: $7.49B
valuation
21.4x
LAST: $136.01 (-5.83%) • MKT CAP: $7.57B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. AXSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | AXSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | -21.90% | +36.00 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | -1.25% | +4.88 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | -26.10% | +39.20 | AMRX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | -28.70% | +31.10 | AMRX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 65.50% | -57.50 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.34 | -1.51 | AXSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.6 | 25.9 | +40.70 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 35.0x | +61.00 | AXSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.49B | $7.57B | -$73.5M | AXSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | AXSM REV | AMRX GROSS % | AXSM GROSS % | AMRX FCF | AXSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $638.5M | 36.9% | — | $269.9M | -$93.9M |
| FY 2024 | $2.79B | $385.7M | 36.5% | — | $243.2M | -$128.7M |
| FY 2023 | $2.39B | $270.6M | — | — | $237.9M | -$157.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
AXSM // BETA 1.15